home / stock / lumo / lumo short
Short Information | Lumos Pharma Inc. (NASDAQ:LUMO)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 38,430 |
Total Actual Volume | 219,668 |
Short Trends | |
---|---|
Cover Days | 17 |
Short Days | 2 |
No Change Days | 1 |
Averages | |
---|---|
Average Short Volume | 1,922 |
Average Short Percentage | 22.19% |
Is there a LUMO Short Squeeze or Breakout about to happen?
See the LUMO Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
07-02-2024 | $2.32 | $2.27 | $2.32 | $2.17 | 12,201 | 1,355 | 11.11% |
07-01-2024 | $2.25 | $2.263 | $2.38 | $2.25 | 23,985 | 1,760 | 7.34% |
06-28-2024 | $2.25 | $2.32 | $2.32 | $2.25 | 952 | 220 | 23.11% |
06-27-2024 | $2.2501 | $2.2512 | $2.2512 | $2.2301 | 2,528 | 351 | 13.88% |
06-26-2024 | $2.25 | $2.255 | $2.28 | $2.25 | 3,039 | 2,146 | 70.62% |
06-25-2024 | $2.34 | $2.24 | $2.34 | $2.2105 | 3,925 | 515 | 13.12% |
06-24-2024 | $2.2513 | $2.27 | $2.36 | $2.2 | 5,204 | 1,208 | 23.21% |
06-21-2024 | $2.1 | $2.23 | $2.23 | $2.08 | 25,610 | 2,920 | 11.4% |
06-20-2024 | $2.24 | $2.19 | $2.24 | $2.15 | 11,197 | 2,241 | 20.01% |
06-18-2024 | $2.3 | $2.2 | $2.32 | $2.17 | 13,334 | 3,750 | 28.12% |
06-17-2024 | $2.4 | $2.3 | $2.4 | $2.3 | 3,336 | 1,433 | 42.96% |
06-14-2024 | $2.3601 | $2.39 | $2.52 | $2.36 | 13,172 | 21 | 0.16% |
06-13-2024 | $2.46 | $2.49 | $2.545 | $2.46 | 1,909 | 315 | 16.5% |
06-12-2024 | $2.55 | $2.57 | $2.57 | $2.4552 | 8,671 | 5,206 | 60.04% |
06-11-2024 | $2.34 | $2.55 | $2.6046 | $2.245 | 8,916 | 1,046 | 11.73% |
06-10-2024 | $2.5 | $2.41 | $2.6704 | $2.28 | 25,868 | 691 | 2.67% |
06-07-2024 | $2.45 | $2.48 | $2.51 | $2.43 | 5,338 | 464 | 8.69% |
06-06-2024 | $2.35 | $2.51 | $2.5238 | $2.35 | 21,716 | 3,941 | 18.15% |
06-05-2024 | $2.35 | $2.35 | $2.3999 | $2.3 | 4,638 | 1,396 | 30.1% |
06-04-2024 | $2.38 | $2.27 | $2.38 | $2.1043 | 24,129 | 7,451 | 30.88% |
News, Short Squeeze, Breakout and More Instantly...
AUSTIN, Texas, June 04, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced today details of new analyses of data from its Phase 2 OraGrowtH212 clinical trial presented in two posters at the...
AUSTIN, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted f...
Outcome from End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial Updated 12 and 24-Month Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials Continue to Show Oral LUM-201 Achieves Significant Increase in Growth from Baseline, Durable Effect to 24 Months ...